ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Reply to S. Rossi et al and P. Palassin et al.
Abdul Rafeh Naqash, Douglas B Johnson, Javid J Moslehi, Elad Sharon
Abstract readLetterComment
In one paragraphArticle in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
4 authors.
Abdul Rafeh NaqashAbdul Rafeh Naqash, MD, Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK; Douglas B. Johnson, MD, Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN; Javid J. Moslehi, MD, Section of Cardio-Oncology & Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA; and Elad Sharon, MD, MPH, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-7622-720X Douglas B JohnsonAbdul Rafeh Naqash, MD, Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK; Douglas B. Johnson, MD, Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN; Javid J. Moslehi, MD, Section of Cardio-Oncology & Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA; and Elad Sharon, MD, MPH, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-6390-773X Javid J MoslehiAbdul Rafeh Naqash, MD, Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK; Douglas B. Johnson, MD, Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN; Javid J. Moslehi, MD, Section of Cardio-Oncology & Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA; and Elad Sharon, MD, MPH, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Elad SharonAbdul Rafeh Naqash, MD, Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK; Douglas B. Johnson, MD, Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN; Javid J. Moslehi, MD, Section of Cardio-Oncology & Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA; and Elad Sharon, MD, MPH, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-0044-9719 Funding
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9MNovel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3MLong-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3MNHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R01 HL156021
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID36318738
PMCPMC9928682
What OpenQuestion holds
Textmetadata
Read underepoch 390